Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): A potential source for cellular immunotherapy

Leukemia

Volumn 17, Issue 10, 2003, Pages 1973-1980

  Guven, H ^a   Gilljam, M ^a   Chambers, B J ^a   Ljunggren, H G ^a   Christensson, B ^a   Kimby, E ^a   Dilber, M S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B CLL; Cytotoxic cells; Immunotherapy; Killer cells; NK cell; NKT cell

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; FLUDARABINE; MONOCLONAL ANTIBODY; OKT 3; RITUXIMAB; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL POPULATION; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE DEPLETION; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE SUBPOPULATION; BLOOD; CLASSIFICATION; CYTOTOXICITY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE COUNT; METHODOLOGY; MIDDLE AGED; NATURAL KILLER CELL; T LYMPHOCYTE;

AGED; ANTIGENS, CD; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, B-CELL; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0142151230     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403083     Document Type: Article

References (35)

1. Jaffe ES, Harris NL, Stein H, Vardiman J. Pathology and Genetics eds. World Health Organization classification of tumors: Tumors of Hematopoietic and Lymphoid Tissue. Lyon, France: IARC Press, 2001, 84-86.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
4. Montserrat E, Bosch F, Rozman C. Treatment of B-cell chronic lymphocytic leukemia: current status and future perspectives. J Intern Med Suppl 1997, 740: 63-67.
5. Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities. Mayo Clin Proc 1992; 67: 457-461.
6. Esteve J, Montserrat E. Hematopoietic stem cell transplantation for B-cell chronic lymphocytic leukaemia: current status. Rev Clin Exp Hematol 2000; 42: 167-178.
7. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748-758.
8. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
9. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
10. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1997; 230: 221-244.
11. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000; 97: 2731-2736.
12. Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL. Nonsecretory apoptotic killing by human NK cells. J Immunol 1996; 157: 1117-1126.
13. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 2002; 38: 1007-1021.
14. Long EO. Tumor cell recognition by natural killer cells. Semin Cancer Biol 2002; 12: 57-61.
15. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 2001; 181: 158-169.
16. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27: 321-327.
17. Alvarez de Mon M, Casas J, Laguna R, Toribio ML, de Landazuri MO, Durantez A. Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL. Blood 1986; 67: 228-232.
18. Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells. Leukemia Lymphoma 1992; 7: 473-480.
19. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol 1996; 96: 16-23.
20. Foa R, Lauria F, Lusso P, Giubellino MC, Fierro MT, Ferrando ML et al. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1984; 58: 509-516.
21. Kay NE, Zarling J. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol 1987; 24: 161-167.
22. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-583.
23. Joyce S. CD1d and natural T cells: how their properties jump-start the immune system. Cell Mol Life Sci 2001; 58: 442-469.
24. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I et al. Requirement for Valpha 14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623-1626.
25. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R et al. Bone marrow NK1.1 (-) and NK1.1 (+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-1081.
26. Cheson BD, Bennett JM, Grever M. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
27. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001; 62: 1092-1098.
28. Vujanovic NL, Basse P, Herberman RB, Whiteside TL. Antitumor functions of natural killer cells and control of metastases. Methods 1996; 9: 394-408.
29. Lowdell MW, Lamb L, Hoyle C, Velardi A, Prentice HG. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br J Haematol 2001; 114: 11-24.
30. Lefterova P, Schakowski F, Buttgereit P, Scheffold C, Huhn D, Schmidt-Wolf IG. Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy. Haematologica 2000; 83: 1108-1109.
31. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994; 87: 453-458.
32. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3 (+) CD56 (+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92: 3318-3327.
33. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7: 216-222.
34. Gamberale R, Geffner J, Arrosagaray G, Scolnik M, Salamone G, Trevani A et al. Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis. Leukemia 2001; 15: 1860-1867.
35. Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H et al. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol 1997; 58: 5-13.